MarjorieGreenMD

Breast Cancer, Hematologic Oncology

Associate Professor of Medicine

Dr. Green is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001
University of Virginia Medical CenterResidency, Internal Medicine, 1995 - 1998
University of Texas Medical Branch School of MedicineClass of 1995

PubMed

290 citations
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Robert J. Motzer, Romain Banchereau, Habib Hamidi, Thomas Powles, David F. McDermott
Cancer Cell. 2020-12-14
689 citations
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3,...
Brian I. Rini, Thomas Powles, Michael B. Atkins, Bernard Escudier, David F. McDermott
Lancet. 2019-06-15
3307 citations
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles, Alessandra Castiglioni, Kobe C. Yuen
Nature. 2018-02-22

Merck’s Application for KEYTRUDA® (Pembrolizumab) Receives US FDA’s Priority ReviewFebruary 26th, 2025
Merck Gets USFDA Priority Review for Application for Keytruda plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head, Neck Squamous Cell CarcinomaFebruary 26th, 2025
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Met Primary EndpointsNovember 19th, 2024
Join now to see all